查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594470

神经诊断市场：按产品、适应症和最终用户划分 - 全球预测 2025-2030

Neurodiagnostics Market by Product (Clinical Testing Instrument, Diagnostic & Imaging System, Reagent & Consumable), Indication (Epilepsy, Headache Disorder, Neurodegenerative Diseases), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年神经诊断市场价值为73.4亿美元，预计到2024年将达到79.7亿美元，复合年增长率为8.71%，到2030年将达到131.8亿美元。

神经诊断市场包括用于评估和监测神经系统疾病的诊断工具和测试的开发和使用。随着阿兹海默症、癫痫和帕金森氏症等神经系统疾病的盛行率持续上升，对准确诊断方法的需求也随之增加。该市场包括各种应用，例如医疗机构、诊断实验室和学术研究中心的神经成像、体外诊断和神经资讯学。主要成长动力包括人口老化的加剧、神经影像技术的进步以及对微创诊断的需求不断增加。人工智慧驱动的图像分析和可携式脑电图设备的创新为行业参与者提供了充满希望的机会。在更深入的遗传见解和生物标记识别的推动下，个人化医疗为客製化治疗开闢了新途径，推动了患者治疗结果和市场扩张。

主要市场统计
基准年[2023] 73.4亿美元
预测年份 [2024] 79.7亿美元
预测年份 [2030] 131.8亿美元
复合年增长率（%） 8.71%

神经诊断市场的挑战包括与尖端诊断成像设备相关的高成本以及缺乏熟练的专业人员。监管障碍和神经系统疾病的复杂性常常会延迟产品开发和核准流程，造成额外的障碍。为了克服这些挑战，公司应专注于开发具有成本效益的诊断工具并投资于培训计划以缩小专业知识差距。此外，与学术机构的联合研究将有助于发现新的生物标记和治疗药物，并有望扩大市场。创新成熟的领域包括即时监测解决方案和数位医疗技术的集成，以促进早期诊断和远端监测，在远端医疗环境中特别有用。

儘管存在一些障碍，医疗保健支出的持续增长和患者意识的提高表明神经诊断市场前景广阔。对于公司来说，透过利用巨量资料分析和机器学习来提高诊断准确性和患者分层来保持领先地位仍然至关重要。向神经系统疾病诊断不足的新兴市场扩张可能会进一步支持成长。因此，策略伙伴关係和研发投资对于满足全球对神经医疗解决方案不断增长的需求并提供有效的解决方案同时保持竞争力至关重要。

市场动态：快速发展的神经诊断市场的关键市场洞察

供需的动态交互作用正在改变神经诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球神经系统疾病增加
    • 提高患者对早期诊断和有效治疗的认识
    • 扩大创新诊断技术的采用
  • 市场限制因素
    • 与神经诊断设备相关的高成本
  • 市场机会
    • 神经退化性疾病诊断的基因组学和蛋白​​质组学进展
    • 正在进行的神经系统疾病临床试验
  • 市场挑战
    • 缺乏熟练的医疗保健专业人员

波特五力：驾驭神经诊断药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对神经诊断药物市场的影响

外部宏观环境因素在塑造神经诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解神经诊断药物市场的竞争状况

神经诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵神经诊断市场供应商绩效评估

FPNV定位矩阵是评估神经诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘神经诊断市场的成功之路

神经诊断市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球神经系统疾病发生率增加
      • 患者越来越多地寻求疾病的早期诊断以进行有效治疗
      • 扩大创新诊断技术的引进
    • 抑制因素
      • 与神经诊断设备相关的高成本
    • 机会
      • 基因组学和蛋白​​质组学在神经退化性疾病诊断的进展
      • 神经系统疾病的临床试验正在进行中
    • 任务
      • 缺乏熟练的医疗保健专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章神经诊断市场：副产品

  • 临床检测设备
    • NGS设备
    • PCR装置
    • 桑格音序器
  • 诊断和影像系统
    • 血管造影术系统
    • CT扫描仪
    • 脑电图系统
    • 肌电图仪
    • 脑磁图装置
    • 核磁共振系统
    • 正子断层扫描仪
    • 超音波影像成像系统
  • 试剂/耗材
    • 抗体
    • 缓衝
    • 酵素、蛋白质、胜肽
    • 媒体与血清
    • 探测
    • 溶剂

第七章依适应症分類的神经诊断药物市场

  • 癫痫
  • 头痛症
  • 神经退化性疾病
  • 睡眠障碍
  • 中风

第八章神经诊断市场：依最终用户分类

  • 门诊治疗中心
  • 诊断实验室和影像中心
  • 医院/诊所
  • 神经中枢

第九章北美和南美神经诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区神经诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的神经诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories Inc.
  • Adeor Medical AG
  • Advanced Brain Monitoring, Inc.
  • Canon Medical Systems USA, Inc.
  • DEYMED Diagnostic sro
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Koninklijke Philips NV
  • Lifelines Neuro Company, LLC
  • Medtronic PLC
  • Mitsar Co., Ltd.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-030226489D71

The Neurodiagnostics Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.97 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 13.18 billion by 2030.

The neurodiagnostics market entails the development and utilization of diagnostic tools and tests to assess and monitor neurological disorders. As the prevalence of neurological conditions like Alzheimer's, epilepsy, and Parkinson's disease continues to rise, the need for precise diagnostic modalities intensifies. The market encompasses various applications such as neuroimaging, in-vitro diagnostics, and neuro-informatics, catering to healthcare facilities, diagnostic laboratories, and academic research centers. Key growth drivers include the increasing geriatric population, advancements in neuroimaging technologies, and heightened demand for minimally invasive diagnostics. Innovations in AI-driven imaging analysis and portable EEG devices present promising opportunities for industry players. Personalized medicine, driven by deeper genetic insights and biomarker identification, is opening up new avenues for tailored treatments, advancing both patient outcomes and market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 7.34 billion
Estimated Year [2024] USD 7.97 billion
Forecast Year [2030] USD 13.18 billion
CAGR (%) 8.71%

Challenges within the neurodiagnostics market include high costs associated with cutting-edge imaging equipment and a scarcity of skilled professionals. Regulatory hurdles and the complexity of neurological disorders often delay product development and approval processes, posing further barriers. To overcome these challenges, businesses should focus on developing cost-effective diagnostic tools and investing in training programs to bridge the expertise gap. Collaborative research with academic institutions could also expedite the discovery of novel biomarkers and therapeutics, enhancing market growth. Areas ripe for innovation include real-time monitoring solutions and the integration of digital health technologies, which can facilitate early diagnosis and remote monitoring, particularly valuable in telemedicine settings.

Despite some hurdles, the continuous growth in healthcare expenditure, coupled with increased patient awareness, suggests a promising outlook for the neurodiagnostics market. It remains pivotal for companies to stay ahead by leveraging big data analytics and machine learning to refine diagnostic accuracy and patient stratification. Expanding reach in emerging markets, where neurological disorders are underdiagnosed, could further bolster growth. Thus, strategic partnerships and investments in R&D are critical to harness the full potential of neurodiagnostics innovations, ensuring companies remain competitive and effective in addressing the evolving global demands for neurological healthcare solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurodiagnostics Market

The Neurodiagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of neurological disorders worldwide
    • Growing awareness among patients for early disease diagnosis for effective treatment
    • Growing adoption of innovative diagnostic technologies
  • Market Restraints
    • High cost associated with the neurodiagnostic devices
  • Market Opportunities
    • Advances in genomics and proteomics for neurodegenerative disorders diagnosis
    • Ongoing clinical trials for neurological disease
  • Market Challenges
    • Limited availability of skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Neurodiagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurodiagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurodiagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurodiagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurodiagnostics Market

A detailed market share analysis in the Neurodiagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurodiagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurodiagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurodiagnostics Market

A strategic analysis of the Neurodiagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurodiagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Adeor Medical AG, Advanced Brain Monitoring, Inc., Canon Medical Systems USA, Inc., DEYMED Diagnostic s.r.o., F. Hoffmann-La Roche Ltd., GE Healthcare, Koninklijke Philips N.V., Lifelines Neuro Company, LLC, Medtronic PLC, Mitsar Co., Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Neurodiagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Clinical Testing Instrument, Diagnostic & Imaging System, and Reagent & Consumable. The Clinical Testing Instrument is further studied across NGS Instrument, PCR Instrument, and Sanger Sequencer. The Diagnostic & Imaging System is further studied across Angiography System, CT Scanner, EEG System, EMG Device, MEG Device, MRI System, PET Scanner, and Ultrasound Imaging System. The Reagent & Consumable is further studied across Antibody, Buffer, Enzyme, Protein, & Peptide, Media & Sera, Probe, and Solvent.
  • Based on Indication, market is studied across Epilepsy, Headache Disorder, Neurodegenerative Diseases, Sleep Disorder, and Stroke.
  • Based on End User, market is studied across Ambulatory Care Center, Diagnostic Laboratory & Imaging Center, Hospital & Clinic, and Neurology Center.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of neurological disorders worldwide
      • 5.1.1.2. Growing awareness among patients for early disease diagnosis for effective treatment
      • 5.1.1.3. Growing adoption of innovative diagnostic technologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the neurodiagnostic devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in genomics and proteomics for neurodegenerative disorders diagnosis
      • 5.1.3.2. Ongoing clinical trials for neurological disease
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neurodiagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Clinical Testing Instrument
    • 6.2.1. NGS Instrument
    • 6.2.2. PCR Instrument
    • 6.2.3. Sanger Sequencer
  • 6.3. Diagnostic & Imaging System
    • 6.3.1. Angiography System
    • 6.3.2. CT Scanner
    • 6.3.3. EEG System
    • 6.3.4. EMG Device
    • 6.3.5. MEG Device
    • 6.3.6. MRI System
    • 6.3.7. PET Scanner
    • 6.3.8. Ultrasound Imaging System
  • 6.4. Reagent & Consumable
    • 6.4.1. Antibody
    • 6.4.2. Buffer
    • 6.4.3. Enzyme, Protein, & Peptide
    • 6.4.4. Media & Sera
    • 6.4.5. Probe
    • 6.4.6. Solvent

7. Neurodiagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Epilepsy
  • 7.3. Headache Disorder
  • 7.4. Neurodegenerative Diseases
  • 7.5. Sleep Disorder
  • 7.6. Stroke

8. Neurodiagnostics Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Care Center
  • 8.3. Diagnostic Laboratory & Imaging Center
  • 8.4. Hospital & Clinic
  • 8.5. Neurology Center

9. Americas Neurodiagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neurodiagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neurodiagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc.
  • 2. Adeor Medical AG
  • 3. Advanced Brain Monitoring, Inc.
  • 4. Canon Medical Systems USA, Inc.
  • 5. DEYMED Diagnostic s.r.o.
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. GE Healthcare
  • 8. Koninklijke Philips N.V.
  • 9. Lifelines Neuro Company, LLC
  • 10. Medtronic PLC
  • 11. Mitsar Co., Ltd.
  • 12. Natus Medical Incorporated
  • 13. Nihon Kohden Corporation
  • 14. Siemens Healthineers AG
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. NEURODIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEURODIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NEURODIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEURODIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEURODIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ANGIOGRAPHY SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY CT SCANNER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EEG SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EMG DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MEG DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PET SCANNER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY BUFFER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ENZYME, PROTEIN, & PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MEDIA & SERA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PROBE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SOLVENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HEADACHE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SLEEP DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORY & IMAGING CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 293. NEURODIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023